Base Analogs

TLR7 and/or TLR8 activation with base analog

InvivoGen provides the most comprehensive choice of base analog ligands known to activate TLR7 and/or TLR8

Toll-like receptor (TLR) 7 and TLR8 play an important role in the immune response to viral infection. They recognize single-stranded ssRNAs of various origins as well as small synthetic molecules, such as imidazoquinolines and nucleoside analogs.

Several preclinical studies and clinical trials suggest that these synthetic TLR7/8 ligands have the potential to be powerful immunomodulators, vaccine adjuvants, and cancer therapeutics [1]. However, challenges in achieving suitable efficacy while avoiding toxicities remain a significant barrier [1].  Defining their synergistic role in combination with established as well as emerging treatments will enhance their significant potential to further improve therapeutic outcomes [1]. 

InvivoGen offers a growing collection of base analogs able to stimulate TLR7 and/or TLR8 in humans and/or mice. The library comprised derivates of adenine, benzazepine, guanosine, imidazoquinoline, and thiazoquinoline. 

Using our HEK-Blue™ and HEK-Dual™ TLR reporter cell line collection, we define the specificity, activity, and potency of each agonist. Moreover, each lot is highly pure and functionally tested.  For vaccination studies, InvivoGen supplies various TLR7/8 ligands (e.g. R848, R837)  in a pre-clinical VacciGrade™.  

 

Key Features of InvivoGen's Base Analogs

• Potent and selective activators of TLR7 and/or TLR8
• Activity is tested on human and mouse TLR7 and TLR8
• Each lot is highly pure (≥95%) and functionally tested
• High-quality, pre-clinical VacciGrade™ is also available for in vivo studies

 

VacciGrade™ is a high-quality pre-clinical grade. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room*. The absence of bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and/or a TLR2 and TLR4 reporter assay.

 

Read our review on TLR7 and TLR8

 

1. Bhagchandani S, et al., 2021. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Adv Drug Deliv Rev.; 175:113803.